The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Open accessAbstract
Adenocarcinoma of the lung is the most common form of lung cancer, but the cell of origin and the stages of progression of this tumor type are not well understood. We have developed a new model of lung adenocarcinoma in mice harboring a conditionally activatable allele of oncogenic K-ras. Here we show that the use of a recombinant adenovirus expressing Cre recombinase (AdenoCre) to induce K-ras G12D expression in the lungs of mice allows control of the timing and multiplicity of tumor initiation. Through the ability to synchronize tumor initiation in these mice, we have been able to characterize the stages of tumor progression. Of particular significance, this system has led to the identification of a new cell type contributing to the development of pulmonary adenocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179
Self-citationIncreasing complexity of Ras signaling
Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., & Der, C. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202174 · Cited by 1,079
Targeted oncogene activation by site-specific recombination in transgenic mice.
Lakso, M., Sauer, B., Mosinger, B., Lee, E. J., Manning, R. W., Yu, S. H., Mulder, K. L., & Westphal, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6232 · Cited by 680
K-ras is an essential gene in the mouse with partial functional overlap with N-ras
Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 545
Self-citationImproved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice
Mao, X., Fujiwara, Y., & Orkin, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5037 · Cited by 329
K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.
Westra, W. H., Baas, I. O., Hruban, R. H., Askin, F. B., Wilson, K. H., Offerhaus, G. J. A., & Slebos, R. J. C. (1996) · PubMed · Cited by 223
Pulmonary preinvasive neoplasia
Kerr, K. M. (2001) · Journal of Clinical Pathology · doi:10.1136/jcp.54.4.257 · Cited by 220
Fasbender, A., Lee, J. H., Walters, R. W., Moninger, T. O., Zabner, J., & Welsh, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2732 · Cited by 158
Molecular Comparison of Human and Mouse Pulmonary Adenocarcinomas
Malkinson, A. M. (1998) · Experimental Lung Research · doi:10.3109/01902149809087385 · Cited by 152
Modeling human lung cancer in mice: similarities and shortcomings
Tuveson, D. A., & Jacks, T. (1999) · Oncogene · doi:10.1038/sj.onc.1203107 · Cited by 144
Self-citation
Research works printed but not linked: 9
- 10.1002/1097-0142(19820301)49:5<881::AID-CNCR2820490511>3.0.CO;2-7 · doi:10.1002/1097-0142(19820301)49:5<881::aid-cncr2820490511>3.0.co;2-7
- 10.1007/s004280050118 · doi:10.1007/s004280050118
- 10.1002/1097-0142(19900715)66:2<289::AID-CNCR2820660216>3.0.CO;2-6 · doi:10.1002/1097-0142(19900715)66:2<289::aid-cncr2820660216>3.0.co;2-6
- 10.1002/1097-0142(19931015)72:8<2331::AID-CNCR2820720808>3.0.CO;2-E · doi:10.1002/1097-0142(19931015)72:8<2331::aid-cncr2820720808>3.0.co;2-e
- 10.1002/aja.1001670305 · DOI
- Shimasoto (1994) Pulmonary neoplasms. in Diagnostic surgical pathology, ed Sternberg S.S. (Raven Press, New York), 3rd ed. pp 1045–1093.
- Ten Have-Opbroek, 1993, Expression of alveolar type II cell markers in acinar adenocarcinomas and adenoid cystic carcinomas arising from segmental bronchi. A study in a heterotopic bronchogenic carcinoma model in dogs., Am. J. Pathol., 142, 1251
- Ten Have-Opbroek, 1997, The alveolar type II cell is a pluripotential stem cell in the genesis of human adenocarcinomas and squamous cell carcinomas., Histol. Histopathol., 12, 319
- Thaete, 1991, Cells of origin of primary pulmonary neoplasms in mice: Morphologic and histochemical studies., Exp. Lung Res., 17, 219, 10.3109/01902149109064413 · doi:10.3109/01902149109064413
Cited by
Items 201–258 of 258
Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma
Chung, K. M., Singh, J., Lawres, L., Dorans, K. J., Garcia, C., Burkhardt, D. B., Robbins, R., Bhutkar, A., Cardone, R., Zhao, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.062 · Cited by 150
Self-citationC-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D
Karreth, F. A., Frese, K. K., DeNicola, G. M., Baccarini, M., & Tuveson, D. A. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-10-0044 · Cited by 149
Self-citationMorton, J. P., Karim, S. A., Graham, K., Timpson, P., Jamieson, N., Athineos, D., Doyle, B., McKay, C., Heung, M., Oien, K. A., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.034 · Cited by 148
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Tong, X., Patel, A. S., Kim, E., Li, H., Chen, Y., Li, S., Liu, S., Dilly, J., Kapner, K. S., Zhang, N., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.012 · Cited by 142
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
Kim, W. Y., Perera, S., Zhou, B., Carretero, J., Yeh, J. J., Heathcote, S. A., Jackson, A. L., Nikolinakos, P., Ospina, B., Naumov, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38443 · Cited by 141
An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants
Zafra, M. P., Parsons, M. J., Kim, J., Alonso-Curbelo, D., Goswami, S., Schatoff, E. M., Han, T., Katti, A., Fernandez, M. T. C., Wilkinson, J. E., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0442 · Cited by 139
“Conditional animal models, such as Kras Lox-Stop-Lox (LSL)-G12D and Kras LSL-G12Vgeo mice developed almost 20 years ago (9,10), have been critical tools for dissecting the role of KRAS mutations in tumor development.”
MethodSafran, M., Kim, W. Y., Kung, A. L., Horner, J. W., Depinho, R. A., & Kaelin, W. G. (2003) · Molecular Imaging · doi:10.1162/153535003322750637 · Cited by 134
Combined Mutation of Apc, Kras , and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer
Sakai, E., Nakayama, M., Oshima, H., Kouyama, Y., Niida, A., Fujii, S., Ochiai, A., Nakayama, K. I., Mimori, K., Suzuki, Y., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3303 · Cited by 133
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer
Genovese, G., Carugo, A., Tepper, J., Robinson, F. S., Li, L., Svelto, M., Nezi, L., Corti, D., Minelli, R., Pettazzoni, P., et al. (2017) · Nature · doi:10.1038/nature21064 · Cited by 131
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis
Shaw, A. T., Meissner, A., Dowdle, J. A., Crowley, D., Magendantz, M., Ouyang, C., Parisi, T., Rajagopal, J., Blank, L. J., Bronson, R. T., et al. (2007) · Genes & Development · doi:10.1101/gad.1526207 · Cited by 131
“…and Spry-2 in the lung GENES & DEVELOPMENT 701 rasG12D; Spry-2Fl/Fl. Lung tumors were induced by intranasal instillation of adenovirus expressing Cre (Jackson et al. 2001), and animals were sacrificed after 6 mo. Based on histologic analysis, both the number of tumors as well as the total tumor…”
MethodInfluentialSelf-citationAfatinib restrains K-RAS–driven lung tumorigenesis
Moll, H. P., Pranz, K., Musteanu, M., Grabner, B., Hruschka, N., Mohrherr, J., Aigner, P., Stiedl, P., Brcic, L., Laszlo, V., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2301 · Cited by 125
The genetics and biology of KRAS in lung cancer
Westcott, P. M. K., & To, M. D. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.012.10098 · Cited by 116
Reichert, M., Takano, S., von Burstin, J., Kim, S.-B., Lee, J.-S., Ihida-Stansbury, K., Hahn, C., Heeg, S., Schneider, G., Rhim, A. D., et al. (2013) · Genes & Development · doi:10.1101/gad.204453.112 · Cited by 112
The ERBB network facilitates KRAS-driven lung tumorigenesis
Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2565 · Cited by 111
“129S4-Krastm4Tyj/J) mice (40) were obtained from the National Cancer Institute (NCI) mouse repository at Frederick, MD.”
MethodAn LKB1–SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation
Murray, C. W., Brady, J. J., Tsai, M. K., Li, C., Winters, I. P., Tang, R., Andrejka, L., Ma, R. K., Kunder, C. A., Chu, P., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1237 · Cited by 111
Best, S. A., Ding, S., Kersbergen, A., Dong, X., Song, J.-Y., Xie, Y., Reljic, B., Li, K., Vince, J. E., Rathi, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12164-y · Cited by 108
IL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cells
Chen, X., Cai, G., Liu, C., Zhao, J., Gu, C., Wu, L., Hamilton, T. A., Zhang, C.-J., Ko, J., Zhu, L., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20171849 · Cited by 106
Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF
Cisowski, J., Sayin, V. I., Liu, M., Karlsson, C., & Bergo, M. O. (2016) · Oncogene · doi:10.1038/onc.2015.186 · Cited by 104
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis
Lauchle, J. O., Braun, B. S., Loh, M. L., & Shannon, K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20644 · Cited by 94
Tang, K.-J., Constanzo, J. D., Venkateswaran, N., Melegari, M., Ilcheva, M., Morales, J. C., Skoulidis, F., Heymach, J. V., Boothman, D. A., & Scaglioni, P. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2603 · Cited by 91
Short-term gain, long-term pain: the senescence life cycle and cancer
Chan, A. S. L., & Narita, M. (2019) · Genes & Development · doi:10.1101/gad.320937.118 · Cited by 80
Peschard, P., McCarthy, A., Leblanc-Dominguez, V., Yeo, M., Guichard, S., Stamp, G., & Marshall, C. J. (2012) · Current Biology · doi:10.1016/j.cub.2012.09.013 · Cited by 82
“RALA and RALB Act Redundantly in RAS-Driven Tumorigenesis To investigate the functions of RALA and RALB in RAS-mediated tumorigenesis, we crossed the Ral-targeted mice to the LSL-Kras non-small cell lung carcinoma (NSCLC) model, where the expression of an oncogenic allele of Kras requires the excision of a LoxP-stop-L…”
HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer
Kalisz, M., Bernardo, E., Beucher, A., Maestro, M. A., del Pozo, N., Millán, I., Haeberle, L., Schlensog, M., Safi, S. A., Knoefel, W. T., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019102808 · Cited by 77
Rare codons capacitate Kras-driven de novo tumorigenesis
Pershing, N. L. K., Lampson, B. L., Belsky, J. A., Kaltenbrun, E., MacAlpine, D. M., & Counter, C. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77627 · Cited by 77
In vivo reprogramming drives Kras-induced cancer development
Shibata, H., Komura, S., Yamada, Y., Sankoda, N., Tanaka, A., Ukai, T., Kabata, M., Sakurai, S., Kuze, B., Woltjen, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04449-5 · Cited by 76
Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression
Rielland, M., Cantor, D. J., Graveline, R., Hajdu, C., Mara, L., de Diego Diaz, B., Miller, G., & David, G. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72619 · Cited by 76
“We next investigated whether Sin3B inactivation affects the progression of KRasG12D-driven PanINs by crossing Sin3Bp–/– mice with Cre-inducible Lox-STOP-Lox-KRasG12D mice (37).”
RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
Miller, M. S., & Miller, L. D. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2011.00100 · Cited by 76
HDAC2 promotes loss of primary cilia in pancreatic ductal adenocarcinoma
Kobayashi, T., Nakazono, K., Tokuda, M., Mashima, Y., Dynlacht, B. D., & Itoh, H. (2017) · The EMBO Reports · doi:10.15252/embr.201541922 · Cited by 75
“We next examined mouse primary Kras/G12D-expressing pancreatic duct epithelial cells (KrasPDEC) that are recognized as potential cells of origin for PDAC [26 – 28].”
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma
Li, Z., Zhuang, X., Pan, C.-H., Yan, Y., Thummalapalli, R., Hallin, J., Torborg, S., Singhal, A., Chang, J. C., Manchado, E., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0289 · Cited by 74
Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
Muzumdar, M. D., Dorans, K. J., Chung, K. M., Robbins, R., Tammela, T., Gocheva, V., Li, C. M.-C., & Jacks, T. (2016) · Nature Communications · doi:10.1038/ncomms12685 · Cited by 72
Self-citationAssessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3438 · Cited by 67
Tu, Q., Hao, J., Zhou, X., Yan, L., Dai, H., Sun, B., Yang, D., An, S., Lv, L., Jiao, B., et al. (2018) · Oncogene · doi:10.1038/onc.2017.316 · Cited by 66
Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines
Vartanian, S., Bentley, C., Brauer, M. J., Li, L., Shirasawa, S., Sasazuki, T., Kim, J.-S., Haverty, P., Stawiski, E., Modrusan, Z., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394130 · Cited by 65
Elsum, I. A., Yates, L. L., Pearson, H. B., Phesse, T. J., Long, F., O'Donoghue, R., Ernst, M., Cullinane, C., & Humbert, P. O. (2014) · Oncogene · doi:10.1038/onc.2013.498 · Cited by 60
Multifaceted role for p53 in pancreatic cancer suppression
Mello, S. S., Flowers, B. M., Mazur, P. K., Lee, J. J., Müller, F., Denny, S. K., Ferreira, S., Hanson, K., Kim, S. K., Greenleaf, W. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211937120 · Cited by 55
Arid1a restrains Kras-dependent changes in acinar cell identity
Livshits, G., Alonso-Curbelo, D., Morris, J. P., Koche, R., Saborowski, M., Wilkinson, J. E., & Lowe, S. W. (2018) · eLife · doi:10.7554/elife.35216 · Cited by 48
Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression
DeBlasi, J. M., Falzone, A., Caldwell, S., Prieto-Farigua, N., Prigge, J. R., Schmidt, E. E., Chio, I. I. C., Karreth, F. A., & DeNicola, G. M. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3848 · Cited by 49
“To understand how Keap1 or Nrf2 mutation affect lung tumor initiation and early progression, we 281 crossed Keap1/Nrf2 mutant mice with the KrasG12D/+ model of early lung adenocarcinoma (40).”
Phosphorylation of FADD by the kinase CK1α promotes KRAS G12D -induced lung cancer
Bowman, B. M., Sebolt, K. A., Hoff, B. A., Boes, J. L., Daniels, D. L., Heist, K. A., Galbán, C. J., Patel, R. M., Zhang, J., Beer, D. G., et al. (2015) · Science Signaling · doi:10.1126/scisignal.2005607 · Cited by 48
“Kras; Rosa26mice (17, 18) were crossed with Csnk1a to generate KCLuc mice (Kras; Luc; Csnk1a).”
BackgroundMethodGenetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis
Mou, H., Moore, J., Malonia, S. K., Li, Y., Ozata, D. M., Hough, S., Song, C.-Q., Smith, J. L., Fischer, A., Weng, Z., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620861114 · Cited by 46
KDM6A regulates cell plasticity and pancreatic cancer progression by noncanonical activin pathway
Yi, Z., Wei, S., Jin, L., Jeyarajan, S., Yang, J., Gu, Y., Kim, H. S., Schechter, S., Lu, S., Paulsen, M. T., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.09.014 · Cited by 41
Frank, K. J., Mulero-Sánchez, A., Berninger, A., Ruiz-Cañas, L., Bosma, A., Görgülü, K., Wu, N., Diakopoulos, K. N., Kaya-Aksoy, E., Ruess, D. A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100815 · Cited by 40
PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung Tumorigenesis
Green, S., Trejo, C. L., & McMahon, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1249 · Cited by 38
“Furthermore, in GEM models, only a fraction of KRAS-expressing lung epithelial cells develop into tumors after variable latency periods (6-8).”
BackgroundMethodInfluentialGao, Y., Päivinen, P., Tripathi, S., Domènech-Moreno, E., Wong, I. P. L., Vaahtomeri, K., Nagaraj, A. S., Talwelkar, S. S., Foretz, M., Verschuren, E. W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2049 · Cited by 40
Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models
Saiki, Y., Jiang, C., Ohmuraya, M., & Furukawa, T. (2021) · Cancers · doi:10.3390/cancers14010071 · Cited by 38
BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer
Li, K., Liu, Y., Ding, Y., Zhang, Z., Feng, J., Hu, J., Chen, J., Lian, Z., Chen, Y., Hu, K., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci161308 · Cited by 37
Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS -driven tumors
Jiang, H., Muir, R. K., Gonciarz, R. L., Olshen, A. B., Yeh, I., Hann, B. C., Zhao, N., Wang, Y.-H., Behr, S. C., Korkola, J. E., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210739 · Cited by 33
“We next evaluated the effects of COBI and TRX-COBI on overall survival in a widely used autochthonous Kras LSL-G12D/+ ; Trp53 flox/flox , ( KP ) mouse lung cancer model (Jackson et al., 2001).”
Nf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence
Wang, X., Min, S., Liu, H., Wu, N., Liu, X., Wang, T., Li, W., Shen, Y., Wang, H., Qian, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809856 · Cited by 33
Guo, X., Liu, Y., Kim, J. L., Kim, E. Y., Kim, E. Q., Jansen, A., Li, K., Chan, M., Keenan, B. T., Conejo-Garcia, J., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212930 · Cited by 23
Paradoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis
Ferri-Borgogno, S., Barui, S., McGee, A. M., Griffiths, T., Singh, P. K., Piett, C. G., Ghosh, B., Bhattacharyya, S., Singhi, A., Pradhan, K., et al. (2020) · Cancers · doi:10.3390/cancers12092695 · Cited by 22
“To understand the functional role of Arid1a in development of pancreatic cancer, we generated LSL-KrasG12D; Arid1afl/fl; Ptf1a-Cre (“KAC”) mice by crossing Arid1afl/fl; Ptf1a-Cre (“AC”) mice with Lox-stop-lox KrasG12D mice [9].”
BackgroundLKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer
Murray, C. W., Brady, J. J., Han, M., Cai, H., Tsai, M. K., Pierce, S. E., Cheng, R., Demeter, J., Feldser, D. M., Jackson, P. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28619-8 · Cited by 22
Differential Cell Susceptibilities to Kras in the Setting of Obstructive Chronic Pancreatitis
Shi, C., Pan, F. C., Kim, J. N., Washington, M. K., Padmanabhan, C., Meyer, C. T., Kopp, J. L., Sander, M., Gannon, M., Beauchamp, R. D., et al. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.07.001 · Cited by 21
Kim, E. Y., Lee, J. G., Lee, J. M., Kim, A., Yoo, H. C., Kim, K., Lee, M., Lee, C., Han, G., Han, J. M., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919846798 · Cited by 21
Chai, T. F., Manu, K. A., Casey, P. J., & Wang, M. (2020) · Oncogene · doi:10.1038/s41388-020-1364-7 · Cited by 20
K‐RasV14I‐induced Noonan syndrome predisposes to tumour development in mice
Hernández‐Porras, I., Schuhmacher, A. J., Garcia‐Medina, R., Jiménez, B., Cañamero, M., de Martino, A., & Guerra, C. (2016) · The Journal of Pathology · doi:10.1002/path.4719 · Cited by 16
Walter, K., Tiwary, K., Trajkovic-Arsic, M., Hidalgo-Sastre, A., Dierichs, L., Liffers, S. T., Gu, J., Gout, J., Schulte, L.-A., Münch, J., et al. (2019) · Stem Cells International · doi:10.1155/2019/8475389 · Cited by 16
Deciphering Cancer Complexities in Genetically Engineered Mice
SIMIN, K., HILL, R., SONG, Y., ZHANG, Q., BASH, R., CARDIFF, R. D., YIN, C., XIAO, A., McCARTHY, K., & DYKE, T. V. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.038 · Cited by 8
“2005), and the LSLK-ras allele (Jackson et al. 2001) have been described.”
BackgroundMethodTheardy, M. S., Takeda, M., Sorokin, A., Chen, S., Yang, Z., Wang, X., Kanikarla, P., Coker, O., Nguyen, P., Wei, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102253 · Cited by 6
(2023) · doi:10.3390/cancers15153985 · Cited by 5
Metadata
- Authors
- Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2001-12-15
- Volume
- 15
- Issue
- 24
- Pages
- 3243-3248
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W1994772304
- Cited by
- 1,898
- References
- 17
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.